Results of a retrospective study show that natalizumab (Tysabri, Biogen Idec/Elan) was safe and associated with reduction in mean annualized relapse rates in patients with pediatric multiple sclerosis ...

Recent research has shed new light on multiple sclerosis (MS) in children, who make up about 3% to 5% of the MS population. At one time, children were thought to not experience disability due to their ...

The Jacobs Neurological Institute at UB has received a $1.8 million, five-year grant from the National Multiple Sclerosis Society to establish at Women and Children's Hospital of Buffalo one of six ...

Early treatment of pediatric-onset relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with substantially slower disability progression than treatment with ...

Brenda Banwell, MD, Chief, Division of Neurology, Professor of Neurology, Perelman School of Medicine at the University of Pennsylvania, said that there are 3 areas of treatment associated with ...

Please provide your email address to receive an email when new articles are posted on . Risk of treatment discontinuation at 2 years was six times higher with moderately effective therapies. Highly ...

Please provide your email address to receive an email when new articles are posted on . Children presented with unique MS symptoms, while adolescents’ issues aligned more with adults. Nearly half of ...

USA, Texas, Austin Investigators examine the use treatment patterns and utilization of disease-modifying therapy in newly diagnosed pediatric patients with multiple sclerosis. SEATTLE — A considerable ...

After 96 weeks, there was no difference in time to first clinical relapse of multiple sclerosis with teriflunomide compared with placebo. Teriflunomide was well tolerated - serious adverse events ...

Children living with multiple sclerosis (MS) show signs of accelerated biological aging, even in their teenage years. This is according to new research from scientists at the University of California ...

While diagnostic criteria for typical multiple sclerosis (MS) perform well in people ages 18 to 50, differential diagnoses in pediatric-onset MS and late-onset MS require specific considerations.